“We finally have a targeted therapy that can improve patient outcomes. The next step is to make it work better, and in more patients. With our new tools and approaches, we are in a unique position to successfully tackle this challenge.”
— Jérôme Fortin, PhD, Principal Investigator, The Neuro
Astrocytomas and oligodendrogliomas are both types of gliomas, which means they are tumours that arise from the brain’s supportive glial cells. Together they represent an important focus of current brain cancer research. Even when detected early, only 50% of patients survive, and almost always with devastating side effects from surgery and radiotherapy; a grade 4 tumour of this kind is a fatal diagnosis. For patients and families, this creates a prolonged and uncertain journey—one where managing tumour growth and maintaining quality of life are equally important goals.
Understanding Treatment Response to Vorasidenib
In the last year, research reached an important milestone with the development of vorasidenib, a targeted therapy. Unlike traditional treatments that aim to destroy cancer cells, vorasidenib targets the underlying biology of the disease. It acts on cancer stem cells—the cells believed to drive tumour growth and recurrence—encouraging them to mature into non-dividing, inactive cells. By neutralizing the tumour’s capacity to grow, this approach introduces a fundamentally new therapeutic strategy.
For the first time, a targeted therapy specifically designed for a key subtype of tumours—IDH—mutant gliomas, which include astrocytomas and oligodendrogliomas — is demonstrating meaningful clinical impact. This marks a significant shift in the field, moving beyond conventional treatments such as surgery, radiation, and chemotherapy toward more precise, biology driven approaches.
Early clinical results have been highly encouraging. For the first time, researchers have demonstrated in patients that targeting tumour stem cells can slow disease progression. This finding validates years of research and confirms that these cells represent a viable and important therapeutic target in brain cancers.
However, vorasidenib is not yet a complete solution because not all patients respond to treatment. Understanding the biological mechanisms behind this resistance remains a critical priority. Rather than relying on a single drug, researchers are exploring how vorasidenib can be paired with other treatments to enhance its effectiveness.
By identifying complementary mechanisms and targeting multiple pathways simultaneously, these strategies aim to improve response rates and extend the duration of treatment benefit. Importantly, many of the drugs being considered for combination therapy are already approved for other conditions, raising the possibility of faster clinical implementation.
In 2025, a new program was launched in which patients receive vorasidenib while their tumours are being analyzed in real time using advanced molecular techniques. By closely monitoring how different cell populations respond, researchers can identify resistant cells and uncover the mechanisms driving treatment failure.
This integrated model marks a significant advancement in research, allowing discoveries to unfold alongside patient care and accelerating progress toward more effective, personalized therapies. With the study now under review by the Health Canada-PHAC Research Ethics Board, its anticipated launch in the coming months represents an exciting step forward.





